ContractMaster Clinical Trial Agreement • January 23rd, 2017
AMENDMENT NO. 1to the Master Clinical Trial Agreement dated as of 28 June 2016 (“Agreement”) DODATEK č. 1K Rámcové Smlouvě o klinickém hodnocení uzavřenou dne 28.06.2016 (“Smlouva”) by and between Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vienna, AustriaVAT-ID-No.: ATU 64226215(hereinafter referred to as "Sponsor") Uzavřena mezi Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vienna, AustriaDIČ: ATU 64226215(dale jen „Zadavatel”) and Fakultní nemocnice Olomouc,I.P. Pavlova 6, 779 00 Olomouc Responsible unit: doc. MUDr. Roman Havlík, Ph.D., ředitel VAT-ID-No. resp. Taxpayer Ident. No.: 00098892/ CZ00098892(hereinafter referred to as "Institution") a Fakultní nemocnice Olomouc,I.P. Pavlova 6, 779 00 Olomouc, Czech RepublicOdpovědný útvar: doc. MUDr. Roman Havlík, Ph.D., ředitel DIČ/IČ:00098892/ CZ00098892(dále jen „Zdravotnické zařízení“) WHEREAS, Sponsor and Institution have entered into the Agreement. WHEREAS, Sponsor and Institution desire
MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • April 16th, 2020 • Immatics B.V. • Texas
This Master Clinical Trial Agreement (this “Agreement”) is entered into as of December 1, 2016 (the “Effective Date”), by and between Immatics US, Inc. (“Sponsor”), having a principal place of business at 2130 Holcombe, Suite 11.3000, Houston, Texas 77030 and The University of Texas MD Anderson Cancer Center (“Study Site”), an agency of the State of Texas and a member institution of The University of Texas System (“System”), located at 1515 Holcombe Blvd., Houston, Texas 77030. Sponsor and the Study Site are sometimes referred to herein individually as a “Party” and collectively as “Parties.”
Exhibit 10.11 MASTER CLINICAL TRIAL AGREEMENT THIS MASTER CLINICAL TRIAL AGREEMENT (the "Agreement") is effective January 9, 2006 (the "Effective Date") between Cleveland Clinic Florida, a Florida not-for-profit corporation ("CCF"), and Ivivi...Master Clinical Trial Agreement • June 19th, 2006 • Ivivi Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New Jersey
THIRD AMENDMENT TO THE MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • September 17th, 2014
This Third Amendment (“Third Amendment”) effective as of September 16, 2014 hereby amends the Master Clinical Trial Agreement dated March 16, 2009, Amendment #1 thereto dated May 31, 2012, and Amendment #2 thereto dated March 16, 2014, between The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Southwestern Medical Center, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Tyler and The University of Texas at Austin, (individually and collectively referred to as an “Institution”) and Hoffmann-La Roche Inc. and Roche Laboratories Inc. (each referred to as “Roche”) (the “Master Agreement (as amended)”) (each a “Party” and collectively the “Parties”).
ContractMaster Clinical Trial Agreement • August 29th, 2023
AMENDMENT NO. 1to theMaster Clinical Trial Agreement dated as of 23.05.2016 (“Agreement”) DODATEK Č.1 k Rámcové smlouvě o klinickém hodnocení podepsané dne 23.5.2016(dale jen “Smlouva) by and between Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vienna AustriaVAT-ID-No.: ATU 64226215(hereinafter referred to as "Sponsor") mezi Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11,1121 Vídeň, RakouskoDIČ: ATU 64226215(dále Jen „Zadavatel“) and Institute of Rheumatology, Na Slupi 4, 128 50, Prague 2 Responsible unit: Department of Clinical TrialsVAT-ID-No. resp. Taxpayer Ident. No.:CZ000237238(hereinafter referred to as "Institution") a Revmatologický ústav, Na Slupi 4, 128 50, Praha 2 Odpovědný útvar:Oddělení Klinických Hodnocení DIČ/IČ: CZ00023728(Dále Jen „Zdravotnické Zařízení“) WHEREAS, Sponsor and Institution have entered into the Agreement. WHEREAS, Sponsor and Institution desire to continue the successful relationship by altering the Agreement in ce
MASTER CLINICAL TRIAL AGREEMENT(“Agreement”) entered into as of 20 October 2016 (the "Effective Date") by and between Boehringer Ingelheim RCV GmbH & Co KGDr. Boehringer-Gasse 5-11, 1121 Vienna, AustriaVAT-ID-No.: ATU 64226215("Sponsor”) andGeneral...Master Clinical Trial Agreement • November 7th, 2020
RECITALS WHEREAS, Sponsor, a research-driven pharmaceutical company, is sponsoring and conducting a clinical trials of various compounds (“Investigational Product”) according to a specific Clinical Trial Protocol for each clinical trial (“Protocol”); and WHEREAS, Institution may, subject to written agreement, participate as an investigative site in one or more clinical trials (hereinafter referred to as “Trial” and collectively the “Trials”); and WHEREAS, Sponsor may engage a Contract Research Organisation (“CRO”), to act as an independent contractor, but not as a party to this Agreement, to carry out on behalf of Sponsor certain of Sponsor’s responsibilities with respect to the Trial, which may include, but are not limited to, contract negotiation and management, site payment, site monitoring, and/or other Trial related activities; and WHEREAS, Sponsor seeks to engage the services of Institution to carry out a Trial in accordance with the Protocol; and WHEREAS, Institution operates a
NEURONEXT MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • February 2nd, 2018 • Massachusetts
MASTER CLINICAL TRIAL AGREEMENT Sponsor-Initiated Studies OnlyMaster Clinical Trial Agreement • July 15th, 2009 • Texas
This Master Clinical Trial Agreement ("Agreement") is entered into by and between NeoPharm, Inc. with principal offices located at 150 Field Drive, Suite 195, Lake Forest, IL 60045 ("NeoPharm") and each of The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas MD Anderson Cancer Center, The University of Texas Health Center at Tyler, The University of Texas Medical Branch at Galveston, and The University of Texas Southwestern Medical Center at Dallas (each an "Institution", and collectively "Institutions"), each with an office and place of business as set forth on Exhibit B hereto, and each a component institution of The University of Texas System located at 201 West 7th Street, Austin TX 78701 ("System"). Each Institution and NeoPharm may be referred to individually as a "party", and jointly as "parties". This agreement is effective as of the date of full execution ("Effective Date").
FOURTH AMENDMENT TO THE MASTER CLINICAL TRIAL AGREEMENTMaster Clinical Trial Agreement • December 1st, 2014
This Fourth Amendment (“Fourth Amendment”) effective as of November 16, 2014 hereby amends the Master Clinical Trial Agreement dated March 16, 2009, Amendment #1 thereto dated May 31, 2012, and Amendment #2 thereto dated March 16, 2014, and Amendment #3 thereto dated September 16, 2014, between The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Southwestern Medical Center, The University of Texas Medical Branch at Galveston, The University of Texas Health Science Center at Tyler and The University of Texas at Austin, (individually and collectively referred to as an “Institution”) and Hoffmann-La Roche Inc. and Roche Laboratories Inc. (each referred to as “Roche”) (the “Master Agreement (as amended)”) (each a “Party” and collectively the “Parties”).
NOTE: This document is only a template. It is subject to change depending upon the specific needs of a study. In order for it to be considered ready for execution, it must be reviewed by the IU Clinical Trials Office and agreed upon by the applicable...Master Clinical Trial Agreement • August 13th, 2015 • Indiana
THIS MASTER CLINICAL TRIAL AGREEMENT (the “Agreement”) is made and entered into as of the _______ day of ________, 2016 (hereinafter, the “Effective Date”), by and between __________________________[Insert Sponsor Name], (hereinafter, “SPONSOR”), on behalf of itself, and its affiliates, with offices at____________________________ [Insert Sponsor Address}, and TRUSTEES OF INDIANA UNIVERSITY (hereinafter, “INSTITUTION”), with offices at Clinical Trials Office, 410 West 10th Street, Suite 1020, Indianapolis, IN 46202. For purposes of this Agreement, SPONSOR and INSTITUTION (as defined below) may be referred to individually as a “Party”, and collectively as the “Parties”.
